Treatment(s) already received-None Page 3 Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Comparing prostate surgery with radiotherapy and radiotherapy with androgen deprivation therapy for advanced prostate cancer

Posted by on Oct 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the long-term effects of two treatment combinations for advanced prostate cancer. This study found that surgery and radiotherapy had improved overall survival in comparison with radiotherapy plus androgen deprivation therapy (ADT) in these patients, but with higher rates of side-effects. Some background...

Read More

Is a low-intensity chemotherapy treatment plan safe and effective for elderly patients with Acute Myeloid Leukemia?

Posted by on Sep 6, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to create a safe and effective low-intensity chemotherapy treatment plan for elderly patients with AML . This is an ongoing clinical trial and so far the authors have found the therapy has been safe and effective. Some background Outcomes for elderly patients with AML in the past have not been good due to the high...

Read More

Evaluating the BR regimen in patients with low-tumor burden follicular lymphoma

Posted by on Sep 4, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR regimen (rituximab, bendamustine) in elderly patients with untreated low-tumor burden follicular lymphoma (LTBFL). This study concluded that the BR regimen may provide positive outcomes for these patients. Some background Low-tumor burden follicular lymphoma (LTBFL) is a type of...

Read More

Looking for patients with triple negative breast cancer to test atezolizumab

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Which is more effective in secondary acute myeloid leukemia, FLAG or standard 7+3 induction therapy?

Posted by on Jul 3, 2018 in Leukemia | 0 comments

In a nutshell This study analyzed different types of induction chemotherapy regimes in secondary acute myeloid leukemia. The authors concluded that the FLAG combination had a high response rate and a low level of treatment-related side effects. Some background Secondary acute myeloid leukemia is a type of leukemia arising from a pre-existing...

Read More

Comparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma

Posted by on Jul 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...

Read More